Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.

new patent Rigel Pharmaceuticals, Inc.
. .

new patent Methods and compositions for the treatment of cancer or other diseases
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
City Of Hope


new patent Composition enriched in anti-a and/or anti-b polyclonal immunoglobulins for use in the treatment of autoimmune diseases or polycythemia
The invention relates to a composition strongly enriched with anti-a and/or anti-b polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-a or anti-b polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and/or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies


new patent Therapeutic cd47 antibodies
Provided are anti-cd47 monoclonal antibodies (anti-cd47 mabs) with distinct functional profiles as described herein, methods to generate anti-cd47 mabs, and to methods of using these anti-cd47 mabs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of cd47 in tissue samples.. .
Tioma Therapeutics, Inc.


new patent Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non- overlapping sites in a cytokine and an fc moiety.
Institute For Research In Biomedicine


new patent Autotaxin inhibitors and uses thereof
Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases)..
National And Kapodistrian University Of Athens


new patent Compounds and treating autoimmune diseases
Wherein x and y independently are o or nr1; each r1 is independently h or c1-c6 alkyl; ring a is aryl; each r2 independently is h, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two r2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; r3 and r4 independently are h or c1-c6 alkyl; and r5 is halo, cyano, or c1-c6 alkyl.. .

new patent Targeted nanocarriers for targeted drug delivery of gene therapeutics
A targeted nanocarriers also termed nanomedicines and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme such as a zinc finger nuclease, a crispr/cas system, or a talen) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microrna, a sirna, a mrna, an antisense oligonucleotide, or a sense oligonucleotide) to a range of mammalian cell species. Cell specific targeting is achieved by using nanocarriers featuring suitable targeting anchors having a targeting moiety that can be a carbohydrate, an antibody or an antibody fragment, a non-antibody protein derivative, an aptamer, a lipoprotein or a fragment thereof, a peptidoglycan, a lipopolysaccharide or a fragment thereof, or a cpg dna.
Rodos Biotarget Gmbh


new patent Composition for preventing or treating autoimmune disease, containing ssu72 as active ingredient
The present disclosure relates to a composition for preventing or treating an autoimmune disease, in which the composition includes ssu72 as an active ingredient. According to the present invention, ssu72 has an effect of effectively inhibiting stat3 activity, thereby effectively preventing and treating, ultimately, an immune disease, and preferably, stat3-mediated diseases through an action capable of inhibiting the expression of inflammatory cytokines when ssu72 is overexpressed and simultaneously promoting the expression of il-4 and il-10, which are factors associated with immunoregulatory t cells..
The Catholic University Of Korea Industry- Academic Cooperation Foundation


new patent Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


Nanoparticle conjugates and uses thereof

The targeted delivery of therapeutic agents to specific cells remains a challenge in drug delivery. Provided herein are nanoparticle-targeting agent conjugates that can be used for the targeted delivery of therapeutic agents to certain cells and target tissues.
Massachusetts Institute Of Technology

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Therapeutic ozone agent and treatment

The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

A predicting the risk of incidence of chronic kidney diseases

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin

Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the t cell immunoglobulin and mucin protein-3 (hm-3). The invention provides a tim-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Wherein r1a, r1b, r2, r4, r5, r6, r7, r8, w, x, y, z, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

Inhibitors of leukotriene a4 hydrolase

Pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists

Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Il-2 variants for the treatment of autoimmune diseases

This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an il-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles.
Delinia, Inc.

Probiotic compositions for improving metabolism and immunity

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera ileibacterium and dubosiella, including their species i.
New York University

Takeda Pharmaceutical Company Limited

. .

T-reg cell expansion

This invention relates to methods of expanding t regulatory cells through ox40l and jagged-1 induced signaling. The methods can be used for treating autoimmune diseases..
The Board Of Trustees Of The University Of Illinois

Compositions and methods for diagnosing and treating autoimmune diseases

Disclosed are compositions and methods for detecting, isolating, and/or characterizing a t cell or autoantibody associated with type i diabetes. The composition and methods comprise the use of a hybrid insulin peptide having an n-terminal amino acid sequence taken from the human insulin peptide and a c-terminal amino acid sequence taken from a secretory granule protein that are joined through a peptide bond to form an autoimmune antigen.
The Regents Of The University Of Colorado, A Body Corporate

Imidazo isoindole derivative, preparation method therefor and medical use thereof

The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (i), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the ido-mediated tryptophan metabolic pathways.
Shanghai Hengrui Pharmaceutical Co., Ltd.

Inhibitors of leukotriene a4 hydrolase

The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.

Heterocyclic derivatives modulating activity of certain protein kinases

The present invention relates to novel heterocyclic derivatives having general formula (i) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like alzheimer's or parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (i) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications..
Universita' Degli Studi Di Milano

Small molecule compounds targeting pbx1 transcriptional complex

In accordance with one or more embodiments, the present invention provides a compound of formulas i, ii, and iii, for use in methods of inhibition of pbx1-dna interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.. .
The Johns Hopkins University

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Substituted hydroxystilbenes and their therapeutic applications

It discloses a compound of formula i that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.. .
Resolvex Pharmaceuticals Inc.

Covalent conjugates of bet inhibitors and alpha amino acid esters

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. .
Glaxosmithkline Intellectual Property Development Limited

Insulin mimotopes and methods of using the same

Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive t cells into foxp3+ regulatory t cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes..
National Jewish Health

Methods of preventing and treating autoimmunity

Methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided..
The University Of Florida Research Foundation Incorporated

Methods for the treatment and prevention of inflammatory diseases

The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from helicobacter pylori activates nkt cells in a cd1d-restricted fashion, and is protective against ahr in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by nkt cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative nkt cells and foxp3+ treg cells.
Children's Medical Center Corporation

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical compostion for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting pi3 kinases, thereby being useful in preventing or treating pi3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases..
Korea Research Institute Of Chemical Technology

Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof

The present invention provides compounds pounds of formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i), (ii) or (iii) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (phgdh) in a subject, such as proliferative diseases (e.g., cancers (e.g., breast cancer, er negative breast cancer, melanoma, cervical cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases).
Dana-farber Cancer Institute, Inc.

Therapeutic pooled blood apoptotic cell preparations and uses thereof

Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis.
Enlivex Therapeutics Ltd.

Nissan Chemical Industries, Ltd.

. .

Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnostics Hybrid, Inc.

Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid

The present invention relates to novel solid crystal forms of pomalidomide named form b, form m, pomalidomide:gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis..
F.i.s. - Fabbrica Italiana Sintetici S.p.a.

Treatment of autoimmune disease

Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole pkc inhibitors..
Mingsight Pharmaceuticals, Inc.

Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease

Compositions and methods for measuring c-peptide binding by cells, including cells expressing glut1, using a c-peptide binding facilitator, such as an albumin. Such methods include incubating the cell with a known amount of c-peptide and a c-peptide binding facilitator, and determining the amount of c-peptide bound to the incubated cells.
Board Of Trustees Of Michigan State University

Antibodies directed against interleukin 36 receptor (il-36r)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (il-36r). The invention provides an il-36r-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to human antibodies against human interleukin 2 (il-2) and methods of use of such antibodies for modulating il-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.. .
Musc Foundation For Research Development

Methods and reagents to treat autoimmune diseases and allergy

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen.

Methods of treating immune disorders using pd-1 binding proteins

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. .
Celgene Corporation

Ldl quantitation and methods of use

The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy.

Anti-cd303 monoclonal antibodies

The invention relates to chimeric or humanised anti-cd303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (bpdcn) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Cgas in systemic lupus erythematosus (sle)

The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with ifn-i due to cgas activation. In one aspect, the invention provides compounds of formula (i): [formula should be inserted here] and pharmaceutical uses thereof.
University Of Washington

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Orbital Atk, Inc.

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.

Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system

The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of cns autoimmune diseases, or for the preparation of a pharmaceutical composition for treating cns autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of cns autoimmune diseases.
Hadasit Medical Research Services & Development Limited

Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Glaucocalyxin a derivative and preparation method and application thereof

Provided is a glaucocalyxin a derivative, or salt thereof, as represented by the formula (i), a method for preparation of said glaucocalyxin a derivative, and a use for said glaucocalyxin a derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. Difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer.
Suzhou Pharmavan Cancer Research Center Co., Ltd.

Exosomes sourced from granulocytic myeloid-derived suppressor cells and application thereof

Provided are exosomes sourced from a granulocyte myeloid-derived suppressor cell and an application thereof. The exosomes are named as g-mdsc exo.
Jiangsu University

Novel compound useful for the treatement of degenerative and inflammatory diseases

A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide

A method of reducing pathogenic t-helper cell activity in a human subject in need thereof is disclosed. The method comprises administering to the human subject, known to have a condition mediated by one or more differentiated t-helper cells responsive to cd51, an effective amount of a nitroxide antioxidant, where the nitroxide antioxidant increases cd51 expression, thereby reducing pathogenic t-helper cell activity.

Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

The present invention relates to the field of immunotherapy, in particular, to adoptive t cell therapy, t cell receptor (tcr) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the tcr alpha chain construct (tra) and tcr beta chain construct (trb) of a tcr construct specific for an epitope from an antigen presented on major histocompatibility complex (mhc), comprising contacting t cells isolated from a donor with a library of artificial antigen presenting cells (apc) comprising cells expressing all mhc i or mhc ii alleles present in the donor, preferably, in k562 cells.
Helmholtz Zentrum MÜnchen-deutsches Forschungszentrum FÜr Gesundheit Und

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms..
Rigel Pharmaceuticals, Inc.

Co-crystals of a bruton's tyrosine kinase inhibitor

Disclosed are co-crystals of the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the co-crystals, as well as methods of using co-crystals, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclic Llc

Solvated forms of a bruton's tyrosine kinase inhibitor

Described herein are solvates of the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the solvates, as well as methods of using the solvates, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

18f-labelled folates as pet radiotracers

The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.. .
Merck & Cie

Heterocyclic compounds useful as inhibitors of tnf

Disclosed are compounds of formula (i) or a salt thereof, wherein: x is cr6 or n; w is: (i) —(cr3r3)1-4— or (ii) —(cr3r3)x-y—(cr3r3)y-; and y, r1, r2, r3, r5, r6, r7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of tnfα, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Pglyrp2 biomarker in idiopathic pneumonia syndrome

A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.. .
Case Western Reserve University

Detection of t cell exhaustion or lack of t cell costimulation and uses thereof

The application relates to methods of assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and the use of such methods in determining an individual's risk of autoimmune disease progression, progression of a chronic infection, not responding to a treatment for a chronic infection, not mounting an effective immune response to vaccination, infection-associated immunopathology, transplant rejection, or cancer progression. The application also relates to in vitro methods for assessing whether cd8+ and cd4+ t cells in a sample have an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and for identifying a substance capable of inducing an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype in an individual, as well as a kit for assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype or whether an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype is present in a sample of cd8+ and cd4+ t cells..
Cambridge Enterprise Limited

Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody

Tumor necrosis factor-α (tnfα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of tnf production is implicated in a variety of human diseases including alzheimer's disease, cancer, major depression, and inflammatory bowel disease.
Dnx Biotech, Llc

Mutant hsp70i to prevent autoimmune disease

Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising dna encoding a variant inducible heat shock protein 70 (hsp70i) having a mutation in the dendritic cell binding region thereof (hsp70i435-447) or an isolated variant gene product in the form of hsp70i with a modification in the dendritic cell activating region thereof (hsp70i435-447).. .
Loyola University Of Chicago

Compositions and methods for suppressing or reducing systemic immune response in a subject

The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof..
The Trustees Of The University Of Pennsylvania

Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions

The invention features all-trans retinoic acid (atra)-related compounds capable of associating with pin1 and methods of treating a proliferative disorder characterized by elevated pin1 marker levels, pin1 degradation, and/or reduced pin1 ser71 phosphorylation in a subject by administering an atra-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated pin1 marker levels) by administering an atra-related compound in combination with another therapeutic compound..
Pinteon Therapeutics, Inc.

Synthesis and utility of new capgroup largazole analogs

Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and alzheimer's disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein.
University Of Notre Dame Du Lac

1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof

Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Methods of using chimeric receptors to identify autoimmune disease

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnostic Hybrids, Inc.

Antibody polypeptides that antagonize cd40l

Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited

Bcr-complex-specific antibodies and methods of using same

This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
King's College London

Crystal form of jak inhibitor and preparation method thereof

The present disclosure relates to novel crystalline forms of jak inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis.
Crystal Pharmatech Co., Ltd

Method of treating transplant rejection and autoimmune diseases

A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of su-5416 is disclosed.. .
Wisconsin Alumni Research Foundation

Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.. .
Novartis Ag

Genetically modified mesenchymal stem cell expressing klotho

A genetically modified mesenchymal stem cell (msc) includes an exogenous nucleic acid that includes a klotho encoding region operably linked to a promoter or promoter/enhancer combination. The mscs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as alzheimer's disease (ad), multiple sclerosis (ms), huntington's disease, amyotrophic lateral sclerosis (als), parkinson's disease, and schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases..
Apceth Gmbh & Co. Kg

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein using a linker. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Purinone compounds as kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Devices for detection of antibodies against therapeutic drugs

Devices for detection of antibodies against therapeutic drugs (adas), in which chimeric proteins facilitate immobilization and exposure of target epitopes, are described. Results can be obtained in minutes, enabling point of care testing and/or patient self-testing, and risk assessment.

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Inhibitors of bruton's tyrosine kinase

Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics Llc

Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life

Methods and pharmaceutical compositions for preventing and/or treating acute and chronic inflammation and autoimmune diseases are provided herein. Tumor necrosis factor-α (tnfα) promotes an inflammatory response, which causes clinical problems associated with inflammation and autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma.
Dnx Biotech, Llc

Cell-based composition and use thereof for treatment of psoriasis and autoimmune diseases

A method for the treatment of psoriasis or an autoimmune disease in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.. .
Cytopeutics Sdn. Bhd.

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Beekenkamp Plants B.v.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .
Beekenkamp Plants B.v.

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Fused-ring compounds, pharmaceutical composition and uses thereof

This disclosure is related to a fused-ring compound of formula (i) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (i) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (ido) and/or tryptophan 2, 3-dioxygenase (tdo). This disclosure further provides methods of treating ido and/or tdo-associated diseases, including cancer, viral infection and autoimmune diseases..
Shanghai De Novo Pharmatech Co., Ltd.

Marker sequences for the diagnosis and stratification of systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; ssc) and the markers identified with the aid of this method, which can differentiate between ssc and other autoimmune diseases on the one hand and between different ssc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of ssc.
Protagen Ag

Fcrn antibodies and methods of use thereof

The present invention features antibodies that have high binding affinity to human neonatal fc receptor (fcrn). These anti-fcrn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject..
Momenta Pharmaceuticals, Inc.

Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

The present application discloses a novel fusion peptide of il-2 and il-33 and its use. It comprises a biologically active domain of interleukin-2 (il-2) or a biologically active fragment or homolog thereof, and a biologically active domain of interleukin-33 (il-33) or a biologically active fragment or homolog thereof.
University Of Virginia Patent Foundation

Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.
The Board Of Trustees Of The Leland Stanford Junior University

Tgr5 modulators and methods of use thereof

Or a salt, solvate, hydrate, or prodrug thereof. The compounds of formula a are tgr5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease..

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

Pyridinyl and fused pyridinyl triazolone derivatives

Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk..

Markers of alzheimers disease

The use of markers that participate in inflammatory processes and are associated cytokines in the diagnosis, treatment or prophylaxis of diseases is disclosed. Specifically, cytokines are used to diagnose or treat non-neoplastic or non-leukaemic diseases such as autoimmune diseases or neurodegenerative disorders by the process of taking a dna bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the snp loci at positions −1082, −819 and −592 of the gene encoding il-10.
Immunoclin Ltd.

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hes-mscs are characterized at least in part by the low level of expression of il-6.
Imstem Biotechnology, Inc.

Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting

The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.

Heterocyclic compounds as pi3k-y inhibitors

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Heterocyclic compounds and use thereof

Heterocyclic compounds of formula (i) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation.
National Health Research Institutes

Quinazoline and quinoline compounds and uses thereof

This invention provides compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein t, j, r, r4, rq, o, ra, w and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, and/or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.

Inhibitors of trka kinase

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited

Covalent inhibitors of cdk-7

Wherein r0, r1, r2, r3, r4, r5, and l are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds..

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd

The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“ra”). The method is used in assessing ra in vitro.
Roche Diagnostics Operations, Inc.

Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Novel compound useful for the treatment of degenerative and inflammatory diseases

A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
Galapagos Nv

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Or a salt thereof, wherein r1, r2, r3, r4, r5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds.

Interferon alpha antibodies and their uses

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided.
E. R. Squibb & Sons, L.l.c.

Cyclodextrin-based polymers for therapeutic delivery

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Baylor College Of Medicine

. .

Pan-elr+ cxc chemokine antibodies

Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company

Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factor

Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (probdnf). The binding molecule for probdnf, especially a monoclonal antibody against probdnf, can be used to prevent, mitigate or treat autoimmune diseases..
Shanghai Yile Biotechnology Co., Ltd.

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases

A-x−4x−3x−2x−1-b (seq id no: 3)   (i). .

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

Compounds of formula i: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3 and r4 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of jak kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.. .
Celgene Corporation

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .

Carbazole derivatives

Disclosed are compounds of formula (i): (i) or a salt thereof, wherein q, r1a, r1b, r2a, r2b, r3, r4, r5a, r5b, r6a, r6c, r7a, r7b, r7c, and r7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease

Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a compound as described herein.
The Jackson Laboratory

Compositions and methods for the depletion of cd117+ cells

The invention provides compositions and methods useful for the depletion of cd117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of cd117+ cells in a patient, such as a human.
Magenta Therapeutics, Inc.

Compositions and methods for t cell delivery of therapeutic molecules

The present invention includes compositions and methods for modifying a t cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising t cells, wherein the t cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody.
The Trustees Of The University Of Pennsylania

Compositions containing a spiranthes sinensis extract and pharmaceutical applications thereof

The present disclosure provides compositions and dosage forms comprising sinetirucallol, and methods of using such compositions, such as to treat an inflammation-associated disease, liver fibrosis, wound healing, and/or an autoimmune disease. In some embodiments, the composition comprises a spiranthes sinensis extract..
Spiranthes Biotech, Llc

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles

Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University

Peptides for modulating t-cell activity and uses therof

The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with cd40, thereby interfering with the ability of cd40 to interact with cd154, which is important in inflammation.
The Regents Of The University Of Colorado, A Body Corporate

Bicyclic heteroaryl amine compounds

Disclosed are compounds of formula (i) or a salt thereof; wherein: x is n or ch; q1 is: (i) cl, br, i, —cn, —ch3, or —cf3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 ra and zero to 1 rb; and r1, r2, r3, r4, r5, r6, ra, and rb are defined herein. Also disclosed are methods of using such compounds as modulators of pi3k, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors

Disclosed are compounds of formula (i); or a salt thereof; wherein qi is (i) cl, br, i, —cn, —ch3, or —cf3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with r1; q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with r2 and r3; and r1, r2, and r3 are defined herein. Also disclosed are methods of using such compounds as modulators of pi3k, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Tricyclic atropisomer compounds

Disclosed are compounds of formula (i): or a salt thereof, wherein q is: or; and x, r1a, r1b, r3, r4, and r5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.

Anti-cd52 antibodies

Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation

Antagonistic anti-ox40l antibodies and methods of their use

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-ox40l antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory t cells but also promote the generation and function of regulatory t cells by inducing il-10 and inhibiting tnf-α and by reducing aberrant th2 cell responses.
Baylor Research Institute

Heterocyclic derivatives as rorgamma modulators

The present invention provides novel compounds of formula (i) that are modulators of rorgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of rorgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, fibrotic diseases, or cholestatic diseases..
Genfit

Competitive inhibitors of invariant chain expression and/or ectopic clip binding

The invention relates to methods for modulating the immune function through targeting of clip molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, alzheimer's disease, allergic disease, transplant and cell graft rejection, hiv infection and other viral, bacterial, and parasitic infection, and aids.
Regents Of The University Of Colorado, A Body Corporate

Compositions containing omega-3 oil and uses thereof

The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.

Composition for alleviating nephrotoxicity caused by immunosuppressive drug, comprising metformin, and composition for preventing or treating immune disease, comprising the same

Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects..
The Catholic University Of Korea Industryacademic Cooperation Foundation

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.. .
Nuevolution A/s

Tolerogenic dendritic cells, methods of producing the same, and uses thereof

Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease..
Sotio A.s.

Altering gene expression in cart cells and uses thereof

The present invention relates to compositions and methods for generating a modified t cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of tcr α chain, tcr β chain, beta-2 microglobulin, a hla molecule, ctla-4, pd1, and fas and further comprising a nucleic acid encoding a modified t cell receptor (tcr) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (car). Also included are methods and pharmaceutical compositions comprising the modified t cell for adoptive therapy and treating a condition, such as an autoimmune disease..
The Trustees Of The University Of Pennsylvania

Vista regulatory t cell mediator protein, vista binding agents and use thereof

The present invention relates to a novel regulatory t cell protein. This protein, designated pd-l3 or vista resembles members of the pd-l1 family, identified a novel and structurally-distinct, ig-superfamily inhibitory ligand, whose extra-cellular domain bears homology to the b7 family ligand pd-l1.
The Trustees Of Dartmouth College

Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Compositions and methods for the prevention and treatment of autoimmune conditions

The methods include selectively reducing or expanding t cells according to the antigenic specificity of the t cells. Therefore, the present invention can be used to reduce or eliminate pathogenic t cells that recognize autoantigens, such as beta cell specific t cells.
The General Hospital Corporation

Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient

The present invention relates to an antioxidant composition containing an extracellular polysaccharide produced using ceriporia lacerata, or a mycelium culture of ceriporia lacerata comprising the same, or a dry powder or an extract thereof as an active ingredient. The composition can be used as an antioxidant for preventing or treating various diseases such as brain diseases such as stroke, parkinson's disease, etc., heart diseases, ischemia, arteriosclerosis, skin damage, inflammation, rheumatism, autoimmune diseases, etc.
Fugenbio Co., Ltd.

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Novel anti-inflammatory agents

Disclosed are methods of regulating interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds..
Resverlogix Corp.

Melatonin in autoimmune disease

Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (ms) in a subject who has ms, comprising administering a melatonin agonist to a subject.. .
The Brigham And Women's Hospital, Inc.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor

The application relates to a method for diagnosis of an autoimmune disease, comprising the step of determining the presence or absence of antibodies directed against csa-receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against csa-receptor is indicative of an autoimmune disease in said subject. Furthermore, the application relates to kits comprising c5a-receptor or an immunogenic fragment thereof and the use of csa-receptor..
Cell Trend Gmbh

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fe protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.. .
Nuevolution A/s

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.

Methods of treating autoimmune diseases

Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation

Novel anti-inflammatory agents

Disclosed are methods of regulating interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds..
Resveriogix Corp.

Treatment of allergies and autoimmune diseases

The present disclosure provides a method of treating allergies and autoimmune diseases using microsystem acupuncture. Methods provided herein for treating allergies and autoimmune diseases using microsystem acupuncture involving a novel allergy zone.

Therapeutic agent for autoimmune diseases comprising pd-1 agonist

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients.
Ono Pharmaceutical Co., Ltd.

Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Immunosuppressive blood cells and methods of producing the same

The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .
Universitatsklinikum Heidelberg

Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (mmp9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.. .
Gilead Sciences, Inc.

Methods of treating autoimmune disease using a domain antibody directed against cd40l

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (itp), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company

Anti-cd100 antibodies and methods for using the same

Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100..
Vaccinex, Inc.

Il22 immunoconjugates

The application relates to a conjugate comprising interleukin-22 (il22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ed-a isoform of fibronectin.
Philogen S.p.a.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Artificial antigen-presenting cells and methods for producing and using the same

Described herein are biomimetic janus particles useful as artificial antigen presenting cells capable of activating t cells in vitro. “bull's eye” ligand patterns mimicking either the native or reverse organization of the t cell immunological synapse are provided on the surface of nano- or micro-sized particles.
Indiana University Research And Technology Corporation

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor b-i, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.. .
Rappaport Family Institute For Research In The Medical Sciences

Metallic gold cluster molecules as therapeutic agents for arthritic animals

A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation..

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate mediated macropinocytosis

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .

Oligonucleotide targeted to the a20-three prime untranslated region

An antisense oligonucleotide comprising a sequence targeted to the 3′ untranslated region (3′ utr) of the tnfaip3 (a20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.. .

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Treatment of il-17 mediated disease by blocking sefir-sefir interactions

A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.

Modulators of ror-gamma receptors, composition and use thereof

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject.

Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
University Of Connecticut

Altering gene expression in modified t cells and uses thereof

The present invention relates to compositions and methods for generating a modified t cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of tcr α chain, tcr β chain, beta-2 microglobulin and fas further comprising a nucleic acid encoding a modified t cell receptor (tcr) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (car). Also included are methods and pharmaceutical compositions comprising the modified t cell for adoptive therapy and treating a condition, such as an autoimmune disease..
The Trustees Of The University Of Pennsylvania

Rna polymerase i inhibitors and uses thereof

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .
Tel Hashomer Medical Research Infrastructure And Services, Ltd.

Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.

Immune system modulation for prophylaxis and treatment of diseases and disorders

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms.
Marpe Holdings, Llc

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.

Cholix toxin-derived fusion moelcules for oral delivery of biologically active cargo

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the vibrio cholera cholix gene (ntcholix), a variant of cholix truncated at amino acid a386 (cholix386) and the use of other various cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.
Applied Molecular Transport, Llc

Novel compositions and therapeutic methods

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (ra), atherosclerosis, inflammatory bowel diseases (ibd), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.. .
Ayuvis Research Llc

Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Bioassay for the early detection of autoimmune diseases

Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a biological sample that is not a tear sample from the mammal with an antibody that specifically binds to a first polypeptide selected from the group ctss, ctsh, ctsr, ctsw, ctsz, ifng, il-6ra, il-10, il-10ra, il-15, tnfa, apo-f, or lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided..

Humanized anti-cd22 antibody

Disclosed are humanized rfb4 antibodies or antigen-binding fragments thereof. Therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease.
Immunomedics, Inc.

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation..
The Regents Of The University Of California

Therapeutic uses of cd137pos regulatory t cells in treating autoimmune diseases

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Pharmaceutical compositions comprising soluble cd137

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Methods for treating gi syndrome and graft versus host disease

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctls)-induced killing and by damage to endothelial microvasculture, including radiation-induced gi syndrome, graft vs. Host diseases, inflammatory diseases and autoimmune diseases.
Board Of Regents, The University Of Texas System

Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide..

Methods of treating autoimmunity

Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of d-α-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of d-α-methyldopa..
The Regents Of The University Of Colorado, A Body Corporate

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers..
Vibrant Holdings, Llc

Intracellular osteopontin regulates the lineage commitment of lymphoid subsets

Methods for diagnosing and prognosing autoimmune diseases and t cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (opn-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor bcl6, which is involved in t cell activation/differentiation.
Dana-farber Cancer Institute, Inc.

Fused amino pyridine as hsp90 inhibitors

The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.

Indole compounds and pharmaceutical use thereof

Wherein each symbol is as described in the specification. The invention also provides a method for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like in a mammal by administering the compound or pharmaceutically acceptable salt thereof or solvate thereof to the mammal..

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease

Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle).
Immunomedics, Inc.

Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases

The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or biological medicaments that block and/or inhibit cytokines or cytokine receptors and/or biological medicaments against b cells and/or biological medicaments that inhibit t cell co-stimulation in patients affected by autoimmune diseases, together with methods and kits for said predictive prognosis.. .
Universita' Degli Studi Di Roma "la Sapienza"

Oral administration of an anti-cd20 antibody for treatment of autoimmune disease

The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-cd20 antibody is administered to the subject.

Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory t cells (treg) populations; for treating or ameliorating a vascular inflammation, and kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (wig) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a t cell mediated pediatric vasculitis; kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or juvenile idiopathic arthritis; a neoplastic hematological disorder, or a leukemia..
The Regents Of The University Of California

Indole carboxamide compounds

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis

The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, crohn's disease and ulcerative colitis (uc).. .
Industrial Technology Research Institute

Methods and compositions for modified t cells

The present invention relates to compositions and methods for generating modified cells with nucleic acid encoding a t cell receptor (tcr), a nucleic acid encoding a bispecific antibody, affinity molecule chimeric receptor, bispecific affinity molecule, or a chimeric ligand engineered activation receptor (clear). One aspect includes a method for generating a modified t cell.
The Trustees Of The University Of Pennsylvania

Fgl2 expressing regulatory t cells

This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory t cells (treg) and associated compositions for the induction of immune tolerance are described.
Veritas Therapeutics Inc.

Therapeutic detoxification compositions and methods of making and using same

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.. .
Immutrix Therapeutics, Inc.

Treatments for autoimmune disease

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases.
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Novel imidazopyridazine compounds and their use

This disclosure provides novel imidazopyridazine compounds of formula (i) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting pi3k and potential use in treating a disease responsive to inhibition of pi3k, for example, an inflammatory disease, autoimmune disease or cancer.. .
Hutchison Medipharma Limited

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Modulation of ptpra to treat arthritis

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (pt-pra) antagonist.. .
The Regents Of The University Of California

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Ma, Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Targeted delivery of tertiary amine-containing drug substances

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed..
Seattle Genetics, Inc.

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability

The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
Sanofi

Concentrated methotrexate solutions

Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh

The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Hol

. .

Anti-pd-1 monoclonal antibody and obtaining method therefor

The invention provides human monoclonal antibodies that specifically bind to pd-1 with high affinity. The anti-pd-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed.
Beijing Jingyitaixiang Technology Development Co., Ltd.

Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human cd28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody.
Bristol-myers Squibb Company

Modulating gamma-c-cytokine activity

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Y is c, n or s.. .

Compounds that expand hematopoietic stem cells

The present invention relates to compounds and compositions for expanding the number of cd34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (hscs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense..
Novartis Ag

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions

Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.

Methods and kits for screening transplant recipients and candidates

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease.
National Institute Of Transplantation Foundation

Antibodies specific for mmp9

The present invention relates to new proteins that bind to mmp9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the mmp9 binding proteins according to the invention are able to neutralize mmp9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers.
Merck Patent Gmbh

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases..
Biogen Ma Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Flt3 receptor antagonists

The invention pertains to novel flt3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases..
UniversitÉ De Strasbourg

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Aza-heteroaryl compounds as pi3k-gamma inhibitors

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Supporting immunomodulatory agent

The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing c3-c8 carboxylic acids, their physiologically tolerable salts and/or esters with c1-c8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.. .
Flexopharm Brain Gmbh & Co. Kg

Aptamers for use against autoantibody-associated diseases

The present invention relates to new aptamer molecules for use in the treatment and/or diagnosis of autoimmune diseases associated with autoantibodies against g-protein coupled receptors, a pharmaceutical composition comprising such aptamer molecules, an apheresis column comprising such aptamer molecules and a method for the determination of nucleotide sequences for use as sequences of aptamer molecules.. .
Berlin Cures Holding Ag

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention.
Immunomedics, Inc.

Modified peptides and their use for treating autoimmune diseases

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Immupharma France Sa

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Methods of treating inflammatory and autoimmune diseases and disorders

Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Immunoglobulin constant region fc receptor binding agents

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function.
Gliknik Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Antibody binding to fcrn for treating autoimmune diseases

The present disclosure relates to an isolated anti-fcrn antibody, which is an antibody binding to fcrn (stands for neonatal fc receptor, also called fcrp, fcrb or brambell receptor) that is a receptor with a high affinity for igg or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The fcrn-specific antibody according to the present disclosure binds to fcrn non-competitively with igg to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.

Composition containing smad protein for treatment of autoimmune diseases, a fusion protein comprising smad protein, an expression vector and a preparing the same

The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.. .

Pegylated interferon-beta variant

The present invention provides a pegylated ifn-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the pegylated ifn-β variant as an effective ingredient. The pegylated ifn-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native ifn-β and non-pegylated ifn-β variants, and therefore can be used usefully against various diseases.
Abion Inc.

Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same

The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and pge2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of nr4a2 and/or ubash3b at gene or protein are increased more than 2-fold compared to the immature dendritic cells in addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy..
Jw Creagene Inc.

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Molecules with specificity for cd45 and cd79

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen cd45 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Anti-ilt7 antibody

An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.

Molecules with specificity for cd79 and cd22

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen cd22 and a binding domain specific to the antigen cd79a and/or cd79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.. .
Ucb Biopharma Sprl

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein using a linker. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Surrogates of post-translationally modified proteins and uses thereof

The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
Dummen Group B.v.

Marker sequences for diagnosing and stratifying systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; ssc) and to the markers identified with the aid of this method, which can differentiate between ssc and other autoimmune diseases on the one hand and between different ssc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of ssc.
Protagen Ag

Compositions and methods for the diagnosis of systemic autoimmune disease

The present disclosure relates to the field of molecular biology and immunology. More specifically, the present disclosure provides compositions and methods for detecting anti-th/to autoantibodies in the serum of subject with a systemic autoimmune disease, such as systemic sclerosis (ssc)..
Inova Diagnostics, Inc.

Methods of using cells associated with autoimmune disease

The present invention relates to methods of diagnosing autoimmune disease, predicting suitable treatments of autoimmune disease or identifying autoantigens of autoimmune disease using a population of immunogenic hla-dr+ t cells.. .
Singapore Health Services Pte Ltd.

Novel combinations for antigen based therapy

The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject the subject may have a serum vitamin-d level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an il-10 inducing compound selected from the group consisting of vitamin-d, vitamin-d analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve cd4+ tcells, such as a cyclooxygenase inhibitor, a ctla-4 compound or a tnf alpha inhibitor.
Diamyd Medical Ab

Mth1 inhibitors for treatment of inflammatory and autoimmune conditions

A compound of formula (i), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.. .
Thomas Helledays Stiftelse For Medicinsk Forskning

Treatment of autoimmune disease

Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole pkc inhibitors..
Mingsight Pharmaceuticals, Inc.

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

The specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Pyridine and pyridimine compounds as pi3k-gamma inhibitors

The present disclosure provides compounds of formula i, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .
Incyte Corporation

Use of kukoamine a and kukoamine b

The use of kukoamine a and kukoamine b in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (lps) and unmethylated dna (cpg dna) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use and directionally isolates lead compounds from traditional chinese medicine.
The First Affiliated Hospital, Third Military Medical University, Pla

Dd1alpha receptor and uses thereof in immune disorders

Described herein are methods and compositions for treatment of immune-related diseases or disorders by modulating dd1α activity, alone or in combination with modulation of pd-1 activity. In some embodiments, the methods and compositions described herein are directed to treatment of cancer and/or infections (e.g., bacterial infection, and/or fungal infection).
The General Hospital Corporation

Compositions and methods for autoimmune disease

Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (scnp), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.. .
Nodality, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Pyrrolopyrimidine compounds and their uses

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Astex Therapeutics Ltd.

Takeda Pharmaceutical Company Limited

. .

Autoantibody detection method, testing possibility of autoimmune disease contraction, autoantibody detection reagent, and autoimmune disease test reagent

The present invention provides an autoantibody detection method that can detect an autoantibody causing an autoimmune disease with high accuracy. The autoantibody detection method of the present invention includes the steps of; causing a sample and an antigen reagent comprising a denatured protein presented by an mhc class ii molecule to come into contact with each other; and detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent.
Osaka University

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Bi-terminal pegylated integrin-binding peptides and methods of use thereof

The present invention provides bi-terminal pegylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the peg moieties.
The Regents Of The University Of California

Quinoxaline compounds and uses thereof

This invention provides compounds of formula i and subsets thereof: wherein t, j, r, r4, rq, o, ra, and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Binding molecules specific for il-21 and uses thereof

This disclosure provides il-21 binding molecules, e.g., anti-il-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-il-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof.
Boston Pharmaceuticals Inc.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.

Benzo lipoxin analogues

Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation..
University Of Southern California

Methods of treating autoimmune diseases

Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Syngenta Participations Ag

Canine autoimmune conditions and diagnosis and treatment thereof

The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (snps), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.. .
The Translational Genomics Research Institute

Humanized antibodies against cd269 (bcma

The invention relates to humanized antibodies or antibody fragments that bind cd269 (bcma), thereby disrupting the interaction between cd269 and its native ligands (baff and april), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.. .
Max-delbruck-centrum Fur Molekulare Medizin In Der Helmholtz-gemeinschaft

O-glcnac transferase (ogt) inhibitors and uses thereof

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Methods to treat diseases with protein, peptide, antigen modification and hemopurification

The current invention discloses methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life.

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
University-industry Cooperation Group Of Kyung Hee University

Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory t cells

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory t cells (treg) in an organism and various methods in which the agents according to the invention are used.. .
Aicuris Gmbh & Co. Kg

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof

The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.

Compositions and methods for modulation of rorgammat functions

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-cd20 antibodies for treatment of cd20 positive malignancies and autoimmune diseases.. .
Genentech, Inc.

Ip-10 antibodies and their uses

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Protein kinase inhibitors

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated..
Pharmascience Inc.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
The Walter And Eliza Hall Institute Of Medical Research

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, y, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Composition using metformin for preventing or treating immune diseases including lupus

The present invention relates to a composition for preventing or treating immune diseases through the suppression of b cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of b cell activity which is a cause of disease.
Catholic University Industry Academic Cooperation Foundation

Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.

Aminopyridazinone compounds as protein kinase inhibitors

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.. .
Eternity Bioscience Inc.

Tetrahydroisoquinolinone derivatives and their use in the inhibition of the hsp70 protein

The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis..
Julius-maximilians-universitaet Wuerzburg

Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases

Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody.
Immunomedics, Inc.

Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.. .
Applied Molecular Transport Llc

Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

The present invention relates to the use of leukotriene b4 to enhance the response of toll-like receptor (tlr), rig-i-like receptor (rlr), and nod-like receptor (nlr) when stimulated simultaneously with respective proper ligands. The use in combination of ltb4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders..
Universite De Laval

Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection..

Use of mcoln-1 modulators to regulate cell migration

The present invention relates to the use of modulators of mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.. .

Inhibitor of bruton's tyrosine kinase

Provided are a compound represented by formula (iii) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (iii), and the application of the pharmaceutical compositions as selective inreversible inhibitor of bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant b cell proliferation and cancers.. .

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

Rituximab induction therapy followed by glatiramer acetate therapy

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .

Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

In an embodiment, therapeutic methods and uses of bruton's tyrosine kinase (btk) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a btk inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described..

Antibodies to il-15

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens..
Calypso Biotech Sa

Kv1.3 potassium channel antagonists

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection..
Conogenetix Biosciences Gmbh

Treatment of autoimmune diseases with deep brain stimulation

Techniques using electrical stimulation for treating an autoimmune disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation.
Aleva Neurotherapeutics

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. .
Prothena Biosciences Limited

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine

The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune disease.
Kolltan Pharmaceuticals, Inc.

Heterocyclic compounds as pi3k-y inhibitors

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Method of isolating sphingolipids from cordyceps and their use

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from cordyceps, in particular from wild-type cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities.
Macau University Of Science And Technology

Phosphatidylglycerol as an anti-inflammatory

Compositions and methods for reducing, or inhibiting inflammation in a subject in need thereof have been developed. Pharmaceutical compositions including one or more phosphatidylglycerol (pg), or functional derivatives thereof, in an effective amount to reduce or inhibit inflammation are provided.
Agusta University Research Institute, Inc.

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity..
Universite D'aix-marseille

Antibody which specifically binds to human crth2

There is provided an anti-human crth2 antibody which has desired activity by recognizing and binding to a specific human crth2; the antibody fragment; dna which encodes the amino acid sequence of the antibody; a vector which comprises the dna; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.. .
Kyowa Hakko Kirin Co., Ltd

Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (ms) and hemophilia. In particular, the invention involves the application of a b cell-targeting igg fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Amino sphingoglycolipid analogues

The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.. .

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.

Anti-il-2 antibodies and compositions and uses thereof

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to il-2 and reduce the affinity of il-2 binding to il-2rα and il-2rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same.
The Board Of Trustees Of The Leland Stanford Junior University

Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same

These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting garftase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.. .

Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.. .
Eternity Bioscience Inc.

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1

The invention features all-trans retinoic acid (atra)-related compounds capable of associating with pin1 and methods of identifying the same. The invention also provides methods of treating a condition selected from the group consisting of a proliferative disorder, an autoimmune disease, and an addiction condition characterized by elevated pin1 marker levels, pin1 degradation, and/or reduced pin1 ser71 phosphorylation in a subject by administering a retinoic acid compound.
Beth Israel Deaconess Medical Center, Inc.

Methods of treatment of inflammation of the gut

Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include anandamide.
The University Of Connecticut

Monomers and oligonucleotides comprising cycloaddition adduct(s)

In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring

Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. .
Prothena Biosciences Limited

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
Medimmune Limited

Modulating gamma-c-cytokine activity

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Indolin-2-one or pyrrolo-pyridin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, epilepsy, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems.. .

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Methods for treating or preventing neuroinflammation or autoimmune diseases

Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.. .

Human antibodies to human tnf-like ligand 1a (tl1a)

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

The present invention relates to novel compounds having histone deacetylase 6 (hdac6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (hdac6) inhibitory activity, and are effective for the prevention or treatment of hdac6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders..
Chong Kun Dang Pharmaceutical Corp.

Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions

Disclosed is a method of treating small intestinal bacterial overgrowth (sibo) or a sibo-caused condition in a human subject. Sibo-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and crohn's disease.
Cedars-sinai Medical Center

Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders

The present invention relates to methods, combinations and pharmaceutical compositions for treating or preventing a hemolytic disease or condition in a mammal, wherein: said hemolytic disease or condition is caused by an attack of said mammal's red blood cells by said mammal's own body, or said mammal is a pregnant mammal and said hemolytic disease or condition of a fetus of said pregnant mammal is caused by an attack of said fetus' red blood cells by an antibody of said pregnant mammal, or said mammal is a baby and said hemolytic disease or condition of said baby is caused by an attack of said baby's red blood cells by an antibody of said baby's mother. The exemplary hemolytic diseases or conditions include hemophagocytic lymphohistiocytosis, an autoimmune disease or condition, or a hereditary hemolytic disease or disorder..
Cellics Therapeutics, Inc.

Dgat1 inhibition for treatment of demyelinating inflammatory disease

Methods are provided for treating autoimmune disease in a subject by inhibiting the activity of dgat1.. .
The Board Of Trustees Of The Leland Stanford Junior University

Distinguishing antagonistic and agonistic anti b7-h1 antibodies

Materials and methods for distinguishing agonistic anti-b7-h1 antibodies from antagonistic anti-b7-h1 antibodies, and for treating subjects diagnosed with clinical conditions such as cancer, pathogenic infection, or autoimmune disease.. .
Mayo Foundation For Medical Education And Research

Nucleic acid that inhibits expression of irf5

The present invention provides a nucleic acid having activity to suppress expression of irf5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.. .
Kyowa Hakko Kirin Co., Ltd.

Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof

The present invention provides a fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking baff/appril, and may significantly lower the serum igm concentration in normal balb/c mice as well as the serum igm and ige concentration in c57/b6 mice with asthma.
Shanghai Celgen Bio-pharmaceutical Co., Ltd.

Novel compounds

The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited

Compositions and methods for modulating the immune system

A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Marker sequences for diagnosing and stratifying sle patients

The present invention relates to methods for identifying markers for systemic lupus erythematosus (sle) and to the markers identified with the aid of this method, which can differentiate between sle and other autoimmune diseases on the one hand and between different sle subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in sle.
Protagen Ag

Sequencing-directed selection of tumor theranostics

The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins..
Affigen, Inc.

Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay

Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University

Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto

This disclosure relates to recombinant proteins comprising a gm-csf sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises n-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer..
Children's Healthcare Of Atlanta, Inc.

Suprametallogels and uses thereof

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology

Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

The present invention relates to rearranged molecules of (a) a specific tt virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity.. .
Danziger "dan" Flower Farm

International Nutrition Research Company

. .

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis

The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular

Humanized anti-hla-dr antibodies

The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.

Substituted amino triazoles useful as human chitinase inhibitors

Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.

Indole carboxamide compounds

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways

Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.

Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment

The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Incorporated

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .

Medicament for treating peripheral neuropathies

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes..
The Children's Hospital Of Philadelphia

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Nissan Chemical Industries, Ltd.

. .

Methods of measuring antigen-specific t cells

Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Methods for the diagnostic of an autoimmune disease

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-il2 response, peptides specifically recognised by anti-il2 antibodies or il-2-specific t cells of t1d, systemic lupus erythematosus, rheumatoid arthritis, sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.. .
Universite Paris Descartes

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

2,2'-tandem dithiazole compound, preparation method therefor, and use thereof

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2′-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2′-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type ii diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
Universite Paris Descartes

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Elisa for a naturally-occurring soluble truncated form of il-23 receptor

A naturally-occurring soluble truncated il-23rα protein (i.e., Δ9 il-23rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (elisa) and test kit for the serological detection of the soluble truncated form of il-23rα protein.
Medical Diagnostic Laboratories, Llc

Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd8+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd8+ treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd8+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd8+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd8+ treg cell populations of target tissue a, to identify emigrant cd8+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd8+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd8+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd8+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd4+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd4+ treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd4+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd4+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd4+ treg cell populations of target tissue a, to identify emigrant cd4+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd4+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd4+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd4+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Anti-human il-21 antibodies

Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Zymogenetics, Inc.

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells

Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations.
UniversitÉ De MontrÉal

Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof

The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer..
Biocellchallenge

Pharmaceutical compositions containing beta-2 microglobulin and methods of treating autoimmune diseases

A pharmaceutical product containing β2-microglobulin or a functional variant thereof as an active ingredient in the form of liposomes is provided. The product can increase the concentration of β2-microglobulin in the blood, and can also restore a normal hc/β2-microglobulin molar ratio within membrane mhc-i complexes, or prevent a β2-microglobulin deficit from occurring in the mhc-i complexes, of patients suffering from autoimmune diseases.
Beta Innov

Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases

The invention provides methods for identifying the presence of, or an increased risk of developing, organ damage in a subject having an autoimmune disease, for example, systemic lupus erythematosus (sle) or mixed connective tissue disease (mctd), or other disease in which the lungs and/or kidneys are involved. In one embodiment, a significantly increased combined igm reactivity against the peptides having the sequences of seq id nos: 4, 9, 12, and 15 in a sample obtained from a patient compared to a healthy control indicates lung damage or an increased risk of developing lung damage in the subject.
The Florida International University Board Of Trustees

Use of glycan as biomarkers for autoimmune diseases

The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed..
Macau University Of Science And Technology

Stimulation via tlr4/md-2 to reverse type 1 diabetes

Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati

Anti-bcma antibodies

This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Ma Inc.

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Heterocyclic compounds and uses thereof

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .
Acea Biosciences Inc.

Neosoraphens

The present invention relates to compounds according to general formula (i); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a th17-associated inflammatory and/or autoimmune disease.. .
Twincore Zentrum Für Klinische Infektionsforschung Gmbh

Mmf-derivatives of ethyleneglycols

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Sip modulator immediate release dosage regimen

The present invention relates to siponimod (baf312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.. .

Autoimmunity and multiple sclerosis treatment

A method for alleviating a symptom of multiple sclerosis or other autoimmune or inflammatory disease includes a step of identifying a subject having multiple sclerosis or other autoimmune diseases. A fasting mimicking diet is administered to the subject for a first predetermined time period, the fasting mimicking diet providing less than 50% of the subject's normal caloric intake.
University Of Southern California

Surrogates of post-translationally modified proteins and uses thereof

The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
President And Fellows Of Harvard College

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Combination therapy for the treatment of autoimmune diseases

The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.

Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases

A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

Takeda Pharmaceutical Company Limited

. .

Ddx5 and associated non-coding rnas and modulation of th17 effector function

Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .

Antibody polypeptides that antagonize cd40

Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
Domantis Limited

Inhibitors of bruton's tyrosine kinase

Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Screening the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4

The present invention relates specific activation of a regulatory t cell via a specific cd4 epitope and uses thereof, e.g. For the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction..
Tcf Gmbh

Benzazepine dicarboxamide compounds

Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.

Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors

The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Methods and compositions used in treating inflammatory and autoimmune diseases

Methods of treating neuroinflammation by administration of a selective protein c activator, such as recombinant human we thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation.
The United States Government As Represented By The Department Of Veterans Affairs

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Anti-mcam antibodies and associated methods of use

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer..
Prothena Biosciences Limited

Combination treatment for multiple sclerosis

The present application provides evidence that a combined blockade against alpha-4 integrin and mcam is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an mcam antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease..
University Of Munster

Targeting agent antibody conjugates and uses thereof

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute

Compositions and methods for modulating an immune response

Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.

A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof

The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the th1 and th17 cells, thereby could be used to treat the th1- or th17-mediated autoimmune diseases..
Suzhou Botany Biomedicals Co., Ltd

Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Fused amino pyridine as hsp90 inhibitors

The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.

Derivatives of polyhydroxy compounds

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Compositions and methods for treating immunological dysfunction

The present invention is directed to methods of lymphotherapy to treat cancer, infection and autoimmune disease.. .

Dna vaccines encoding heat shock proteins

A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

Prognostic and diagnostic kits and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Prognostic and diagnostic methods and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.